Cancer risk assessment using genetic panel testing: Considerations for clinical application

Journal of Genetic Counseling

Volumn 23, Issue 4, 2014, Pages 604-617

  Hiraki, Susan ^a   Rinella, Erica S ^b   Schnabel, Freya ^b   Oratz, Ruth ^c   Ostrer, Harry ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cancer panels; Colon cancer; Ovarian cancer; Risk assessment

Indexed keywords

GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; NEOPLASM; RISK ASSESSMENT;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 84904269657     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-014-9695-6     Document Type: Article

References (127)

1. Akushevich, I.; Kravchenko, J.; Akushevich, L.; Ukraintseva, S.; Arbeev, K.; Yashin, A. (2011). Cancer risk and behavioral factors, comorbidities, and functional status in the US elderly population. ISRN Oncology, 2011, 1-9. doi: 10.5402/2011/415790.
2. American Cancer Society recommendations for colorectal cancer early detection. (n.d.). Retrieved April 3, 2013, from http://www.cancer.org/cancer/ colonandrectumcancer/moreinformation/colonandrectumcancerearlydetection/ colorectal-cancer-early-detection-acs-recommendations
3. American Cancer Society recommendations for early breast cancer detection in women without breast symptoms. (n.d.). Retrieved April 3, 2013, from http://www.cancer.org/cancer/breastcancer/moreinformation/ breastcancerearlydetection/breast-cancer-early-detection-acs-recs
4. Antoniou, A.; Pharoah, P. D. P.; Narod, S.; Risch, H. A.; Eyfjord, J. E.; Hopper, J. L.; et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American journal of human genetics, 72(5), 1117-1130. doi: 10.1086/375033.
5. ™ - NCBI Bookshelf. (n.d.). Retrieved April 8, 2013, from http://www.ncbi.nlm.nih.gov/books/ NBK26468/
6. Balmana, J.; Castells, A.; Cervantes, A.; On behalf of the ESMO Guidelines Working Group. (2010). Familial colorectal cancer risk: ESMO clinical practice guidelines. Annals of Oncology, 21(Supplement 5), v78-v81. doi: 10.1093/annonc/mdq169.
7. Barrow, E.; Robinson, L.; Alduaij, W.; Shenton, A.; Clancy, T.; Lalloo, F.; et al. (2009). Cumulative lifetime incidence of extracolonic cancers in lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141-149. doi: 10.1111/j.1399-0004.2008.01125.x.
8. Berg, J. S.; Khoury, M. J.; Evans, J. P. (2011). Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genetics in Medicine, 13(6), 499-504. doi: 10.1097/GIM. 0b013e318220aaba.
9. Berliner, J. L.; Fay, A. M.; Cummings, S. A.; Burnett, B.; Tillmanns, T. (2013). NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of Genetic Counseling, 22(2), 155-163. doi: 10.1007/s10897-012-9547-1.
10. Bernstein, J. L.; Haile, R. W.; Stovall, M.; Boice, J. D.; Shore, R. E.; Langholz, B.; et al. (2010). Radiation exposure, the ATM gene, and contralateral breast cancer in the Women's environmental cancer and radiation epidemiology study. JNCI Journal of the National Cancer Institute, 102(7), 475-483. doi: 10.1093/jnci/djq055.
11. Birch, J. M.; Blair, V.; Kelsey, A. M.; Evans, D. G.; Harris, M.; Tricker, K. J.; et al. (1998). Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene, 17(9), 1061-1068. doi: 10.1038/sj.onc.1202033.
12. Bisgaard, M. L.; Fenger, K.; Bülow, S.; Niebuhr, E.; Mohr, J. (1994). Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Human Mutation, 3(2), 121-125. doi: 10.1002/humu.1380030206.
13. Boardman, L. A.; Thibodeau, S. N.; Schaid, D. J.; Lindor, N. M.; McDonnell, S. K.; Burgart, L. J.; et al. (1998). Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Annals of Internal Medicine, 128(11), 896-899.
14. Bogdanova, N.; Feshchenko, S.; Schürmann, P.; Waltes, R.; Wieland, B.; Hillemanns, P.; et al. (2008). Nijmegen breakage syndrome mutations and risk of breast cancer. International Journal of Cancer, 122(4), 802-806. doi: 10.1002/ijc.23168.
15. Bonadona, V.; Bonaïti, B.; Olschwang, S.; Grandjouan, S.; Huiart, L.; Longy, M.; et al. (2011). Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in lynch syndrome. JAMA: The Journal of the American Medical Association, 305(22), 2304-2310. doi: 10.1001/jama.2011.743.
16. BreastNext | Ambry Genetics. (n.d.). Retrieved October 11, 2013, from http://www.ambrygen.com/tests/breastnext
17. Brosens, L. A. A.; van Hattem, A.; Hylind, L. M.; Iacobuzio-Donahue, C.; Romans, K. E.; Axilbund, J.; et al. (2007). Risk of colorectal cancer in juvenile polyposis. Gut, 56(7), 965-967. doi: 10.1136/gut.2006.116913.
18. Brownstein, M. H.; Wolf, M.; Bikowski, J. B. (1978). Cowden's disease: a cutaneous marker of breast cancer. Cancer, 41(6), 2393-2398.
19. Burt, R. (2007). Inheritance of colorectal cancer. Drug Discovery Today: Disease Mechanisms, 4(4), 293-300. doi: 10.1016/j.ddmec.2008.05.004.
20. Burt, R. W.; Bishop, D. T.; Lynch, H. T.; Rozen, P.; Winawer, S. J. (1990). Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bulletin of the World Health Organization, 68(5), 655-665.
21. Byrnes, G. B.; Southey, M. C.; Hopper, J. L. (2008). Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Research: BCR, 10(3), 208. doi: 10.1186/bcr2099.
22. Casadei, S.; Norquist, B. M.; Walsh, T.; Stray, S.; Mandell, J. B.; Lee, M. K.; et al. (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Research, 71(6), 2222-2229. doi: 10.1158/0008-5472.CAN-10-3958.
23. Chao, S.; Roberts, J. S.; Marteau, T. M.; Silliman, R.; Cupples, L. A.; Green, R. C. (2008). Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Disease and Associated Disorders, 22(1), 94-97. doi: 10.1097/WAD.0b013e31815a9dcc.
24. Chlebowski, R. T. (2002). Weight loss in breast cancer patient management. Journal of Clinical Oncology, 20(4), 1128-1143. doi: 10.1200/JCO.20.4.1128.
25. Cho, M. K.; Sankar, P.; Wolpe, P. R.; Godmilow, L. (1999). Commercialization ofBRCA1/2 testing: practitioner awareness and use of a new genetic test. American Journal of Medical Genetics, 83(3), 157-163. doi: 10.1002/(SICI)1096-8628(19990319)83:3<157::AID-AJMG4>3.0.CO;2-G.
26. Chompret, A.; Brugières, L.; Ronsin, M.; Gardes, M.; Dessarps-Freichey, F.; Abel, A.; et al. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932-1937. doi: 10.1054/bjoc.2000.1167.
27. Collins, V.; Halliday, J.; Kahler, S.; Williamson, R. (2001). Parents' Experiences with genetic counseling after the birth of a baby with a genetic disorder: an exploratory study. Journal of Genetic Counseling, 10(1), 53-72.
28. ColoNext | Ambry Genetics. (n.d.). Retrieved October 11, 2013, from http://www.ambrygen.com/tests/colonext
29. Common Cancer Types - National Cancer Institute. (n.d.). Retrieved October 11, 2013, from http://www.cancer.gov/cancertopics/types/commoncancers#1
30. Comprehensive Cancer Panel - Genetic Testing Company | The DNA Diagnostic Experts | GeneDx. (n.d.). Retrieved September 27, 2013, from http://www.genedx.com/test-catalog/available-tests/comprehensive-cancer-panel/
31. Couch, F. J.; DeShano, M. L.; Blackwood, M. A.; Calzone, K.; Stopfer, J.; Campeau, L.; et al. (1997). BRCA1 Mutations in women attending clinics that evaluate the risk of breast cancer. The New England Journal of Medicine, 336(20), 1409-1415. doi: 10.1056/NEJM199705153362002.
32. Cybulski, C.; Wokolorczyk, D.; Jakubowska, A.; Huzarski, T.; Byrski, T.; Gronwald, J.; et al. (2011). Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. Journal of Clinical Oncology, 29(28), 3747-3752. doi: 10.1200/JCO.2010.34.0778.
33. Desjardins, S.; Joly Beauparlant, C.; Labrie, Y.; Ouellette, G.; BRCAs, I.; Durocher, F. (2009). Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer. BMC Cancer, 9(1), 181. doi: 10.1186/1471-2407-9-181.
34. Domchek, S. M.; Bradbury, A.; Garber, J. E.; Offit, K.; Robson, M. E. (2013). Multiplex genetic testing for cancer susceptibility: Out on the high wire without a Net? Journal of Clinical Oncology, 31(10), 1267-1270. doi: 10.1200/JCO.2012.46.9403.
35. Donnelly, L. S.; Watson, M.; Moynihan, C.; Bancroft, E.; Evans, D. G. R.; Eeles, R.; et al. (2013). Reproductive decision-making in young female carriers of a BRCA mutation. Human Reproduction (Oxford, England), 28(4), 1006-1012. doi: 10.1093/humrep/des441.
36. Elias, S.; Annas, G. J. (1994). Generic consent for genetic screening. The New England Journal of Medicine, 330(22), 1611-1613. doi: 10.1056/NEJM199406023302213.
37. Fletcher, O.; Easton, D.; Anderson, K.; Gilham, C.; Jay, M.; Peto, J. (2004). Lifetime risks of common cancers among retinoblastoma survivors. JNCI Journal of the National Cancer Institute, 96(5), 357-363. doi: 10.1093/jnci/djh058.
38. Ford, D.; Easton, D. F.; Bishop, D. T.; Narod, S. A.; Goldgar, D. E. (1994). Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet, 343(8899), 692-695.
39. Frank, T. S.; Manley, S. A.; Olopade, O. I.; Cummings, S.; Garber, J. E.; Bernhardt, B.; et al. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 16(7), 2417-2425.
40. Gail, M. H. (2011). Personalized estimates of breast cancer risk in clinical practice and public health. Statistics in Medicine, 30(10), 1090-1104. doi: 10.1002/sim.4187.
41. genetics/BROCA - Lab Med Test Info. (n.d.). Retrieved February 4, 2013, from http://web.labmed.washington.edu/tests/genetics/BROCA
42. Getting personal. (2008). Nature, 455(7216), 1007. doi: 10.1038/4551007a.
43. Gilpin, C. A.; Carson, N.; Hunter, A. G. (2000). A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clinical Genetics, 58(4), 299-308.
44. Goldgar, D. E.; Easton, D. F.; Byrnes, G. B.; Spurdle, A. B.; Iversen, E. S.; Greenblatt, M. S. (2008). Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Human Mutation, 29(11), 1265-1272. doi: 10.1002/humu.20897.
45. Gooding, H. C.; Linnenbringer, E. L.; Burack, J.; Roberts, J. S.; Green, R. C.; Biesecker, B. B. (2006). Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Education and Counseling, 64(1-3), 259-267. doi: 10.1016/j.pec.2006.03.002.
46. Green, R. C.; Roberts, J. S.; Cupples, L. A.; Relkin, N. R.; Whitehouse, P. J.; Brown, T.; et al. (2009). Disclosure of APOE genotype for risk of Alzheimer's disease. The New England Journal of Medicine, 361(3), 245-254. doi: 10.1056/NEJMoa0809578.
47. Guilford, P.; Humar, B.; Blair, V. (2010). Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 13(1), 1-10. doi: 10.1007/s10120-009-0531- x.
48. Hearle, N.; Schumacher, V.; Menko, F. H.; Olschwang, S.; Boardman, L. A.; Gille, J. J. P.; et al. (2006). Frequency and spectrum of cancers in the peutz-jeghers syndrome. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(10), 3209-3215. doi: 10.1158/1078-0432.CCR-06-0083.
49. Heikkinen, K. (2005). RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis, 27(8), 1593-1599. doi: 10.1093/carcin/bgi360.
50. Heymann, S.; Delaloge, S.; Rahal, A.; Caron, O.; Frebourg, T.; Barreau, L.; et al. (2010). Radio-induced malignancies after breast cancer post-operative radiotherapy in patients with Li- fraumeni syndrome. Radiation Oncology, 5(1), 104. doi: 10.1186/1748-717X-5-104.
51. Hopper, J. L.; Southey, M. C.; Dite, G. S.; Jolley, D. J.; Giles, G. G.; McCredie, M. R.; et al. (1999). Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 8(9), 741-747.
52. Howe, J. R.; Roth, S.; Ringold, J. C.; Summers, R. W.; Järvinen, H. J.; Sistonen, P.; et al. (1998). Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science (New York, N.Y.), 280(5366), 1086-1088.
53. Howe, J. R.; Sayed, M. G.; Ahmed, A. F.; Ringold, J.; Larsen-Haidle, J.; Merg, A.; et al. (2004). The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. Journal of Medical Genetics, 41(7), 484-491.
54. Hsu, H.-M.; Wang, H.-. C.; Chen, S.-T.; Hsu, G.-. C.; Shen, C.-Y.; Yu, J.-. C. (2007). Breast Cancer Risk Is Associated with the Genes Encoding the DNA Double-Strand Break Repair Mre11/Rad50/Nbs1 Complex. Cancer Epidemiology Biomarkers & Prevention, 16(10), 2024-2032. doi: 10.1158/1055-9965.EPI- 07-0116.
55. Hurley, A. C.; Harvey, F. R.; Roberts, J. S.; Wilson-Chase, C.; Lloyd, S.; Prest, J.; et al. (2005). Genetic susceptibility for Alzheimer's disease: why did adult offspring seek testing? American Journal of Alzheimer's Disease and Other Dementias, 20(6), 374-381.
56. Julian-Reynier, C. M.; Bouchard, L. J.; Evans, D. G.; Eisinger, F. A.; Foulkes, W. D.; Kerr, B.; et al. (2001). Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another. Cancer, 92(4), 959-968. doi: 10.1002/1097-0142(20010815)92:4<959:: AID-CNCR1406>3.0.CO;2-V.
57. Kempers, M. J. E.; Kuiper, R. P.; Ockeloen, C. W.; Chappuis, P. O.; Hutter, P.; Rahner, N.; et al. (2011). Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. The Lancet Oncology, 12(1), 49-55. doi: 10.1016/S1470-2045(10)70265-5.
58. Khoury, M. J.; Gwinn, M.; Yoon, P. W.; Dowling, N.; Moore, C. A.; Bradley, L. (2007). The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genetics in Medicine, 9(10), 665-674. doi: 10.1097/GIM.0b013e31815699d0
59. Khoury, M. J.; Clauser, S. B.; Freedman, A. N.; Gillanders, E. M.; Glasgow, R. E.; Klein, W. M. P.; et al. (2011). Population Sciences, Translational Research, and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century. Cancer Epidemiology, Biomarkers & Prevention, 20(10), 2105-2114. doi: 10.1158/1055-9965.EPI-11-0481.
60. King, M.-. C.; Marks, J. H.; Mandell, J. B.; New York Breast Cancer Study Group. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (New York, N.Y.), 302(5645), 643-646. doi: 10.1126/science.1088759.
61. Lalloo, F.; Evans, D. G. (2012). Familial Breast Cancer. Clinical Genetics, 82(2), 105-114. doi: 10.1111/j.1399-0004.2012.01859.x.
62. Lerman, C.; Croyle, R. (1994). Psychological issues in genetic testing for breast cancer susceptibility. Archives of Internal Medicine, 154(6), 609-616.
63. ™ - NCBI Bookshelf. (n.d.). Retrieved April 8, 2013, from http://www.ncbi.nlm.nih.gov/books/NBK1311/
64. Ligtenberg, M. J. L.; Kuiper, R. P.; Geurts van Kessel, A.; Hoogerbrugge, N. (2012). EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Familial Cancer. doi: 10.1007/s10689-012-9591-x.
65. Marees, T.; Moll, A. C.; Imhof, S. M.; de Boer, M. R.; Ringens, P. J.; van Leeuwen, F. E. (2008). Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. Journal of the National Cancer Institute, 100(24), 1771-1779. doi: 10.1093/jnci/djn394.
66. Martin, S. A.; Lord, C. J.; Ashworth, A. (2010). Therapeutic targeting of the DNA mismatch repair pathway. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16(21), 5107-5113. doi: 10.1158/1078-0432.CCR-10-0821.
67. Masciari, S.; Dillon, D. A.; Rath, M.; Robson, M.; Weitzel, J. N.; Balmana, J.; et al. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 133(3), 1125-1130. doi: 10.1007/s10549-012-1993-9.
68. McBride, C. M.; Lipkus, I. M.; Jolly, D.; Lyna, P. (2005). Interest in testing for genetic susceptibility to lung cancer among Black college students "at risk" of becoming cigarette smokers. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 14(12), 2978-2981. doi: 10.1158/1055-9965.EPI-05-0269.
69. Mealiffe, M. E.; Stokowski, R. P.; Rhees, B. K.; Prentice, R. L.; Pettinger, M.; Hinds, D. A. (2010). Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information. JNCI Journal of the National Cancer Institute, 102(21), 1618-1627. doi: 10.1093/jnci/djq388.
70. Meijers-Heijboer, H.; van den Ouweland, A.; Klijn, J.; Wasielewski, M.; de Snoo, A.; Oldenburg, R.; et al. (2002). Low-penetrance susceptibility to breast cancer due to CHEK2()1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics, 31(1), 55-59. doi: 10.1038/ng879.
71. Meiser, B.; Butow, P.; Friedlander, M.; Schnieden, V.; Gattas, M.; Kirk, J.; et al. (2000). Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 18(11), 2250-2257.
72. Meldrum, C.; Doyle, M. A.; Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. The Clinical Biochemist Reviews/Australian Association of Clinical Biochemists, 32(4), 177-195.
73. Multiplex genetic testing. The Council on Ethical and Judicial Affairs, American Medical Association. (1998). The Hastings Center Report, 28(4), 15-21.
74. Narod, S. A. (2010). Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clinical Genetics, 78(1), 1-7. doi: 10.1111/j.1399-0004. 2010.01402.x.
75. Narod, S. A.; Moody, J. R. K.; Rosen, B.; Fan, I.; Risch, A.; Sun, P.; et al. (2013). Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clinical Genetics, 83(3), 232-237. doi: 10.1111/j.1399-0004.2012.01906.x.
76. Next-gen Cancer Panels | Ambry Genetics. (n.d.). Retrieved February 4, 2013, from http://ambrygen.com/next-gen-cancer-panels
77. Ng, P. C.; Murray, S. S.; Levy, S.; Venter, J. C. (2009). An agenda for personalized medicine. Nature, 461(7265), 724-726. doi: 10.1038/461724a.
78. Nicolaides, N. C.; Papadopoulos, N.; Liu, B.; Wei, Y. F.; Carter, K. C.; Ruben, S. M.; et al. (1994). Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature, 371(6492), 75-80. doi: 10.1038/371075a0.
79. Ormond, K. E.; Wheeler, M. T.; Hudgins, L.; Klein, T. E.; Butte, A. J.; Altman, R. B.; et al. (2010). Challenges in the clinical application of whole-genome sequencing. The Lancet, 375(9727), 1749-1751. doi: 10.1016/S0140-6736(10)60599-5.
80. OvaNext | Ambry Genetics. (n.d.). Retrieved October 11, 2013, from http://www.ambrygen.com/tests/ovanext
81. Peltomäki, P. (2003). Role of DNA mismatch repair defects in the pathogenesis of human cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21(6), 1174-1179.
82. Peltomäki, P.; Vasen, H. F. (1997). Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 113(4), 1146-1158.
83. Pennington, K. P.; Swisher, E. M. (2012). Hereditary ovarian cancer: beyond the usual suspects. Gynecologic Oncology, 124(2), 347-353. doi: 10.1016/j.ygyno.2011.12.415.
84. Pharoah, P.; Guilford, P.; Caldas, C.; Theinternationalgastriccancer. (2001). Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology, 121(6), 1348-1353. doi: 10.1053/gast.2001.29611.
85. Pijpe, A.; Andrieu, N.; Easton, D. F.; Kesminiene, A.; Cardis, E.; Nogues, C.; et al. (2012). Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, 345(sep06 2), e5660-e5660. doi: 10.1136/bmj.e5660.
86. Rahman, N.; Scott, R. H. (2007). Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Human Molecular Genetics, 16(Spec No 1), R60-R66. doi: 10.1093/hmg/ddm026.
87. Rennert, G.; Lejbkowicz, F.; Cohen, I.; Pinchev, M.; Rennert, H. S.; Barnett-Griness, O. (2012). MutYH mutation carriers have increased breast cancer risk. Cancer, 118(8), 1989-1993. doi: 10.1002/cncr.26506.
88. Richards, C. S.; Bale, S.; Bellissimo, D. B.; Das, S.; Grody, W. W.; Hegde, M. R.; et al. (2008). ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 10(4), 294-300. doi: 10.1097/GIM.0b013e31816b5cae.
89. Riley, B. D.; Culver, J. O.; Skrzynia, C.; Senter, L. A.; Peters, J. A.; Costalas, J. W.; et al. (2012). Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 21(2), 151-161. doi: 10.1007/s10897-011-9462-x.
90. Rinella, E. S.; Shao, Y.; Yackowski, L.; Pramanik, S.; Oratz, R.; Schnabel, F.; et al. (2013). Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Human Genetics, 132(5), 523-536. doi: 10.1007/s00439-013-1269- 4.
91. Roberts, J. S.; LaRusse, S. A.; Katzen, H.; Whitehouse, P. J.; Barber, M.; Post, S. G.; et al. (2003). Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Disease and Associated Disorders, 17(2), 86-93.
92. Robson, M. E.; Storm, C. D.; Weitzel, J.; Wollins, D. S.; Offit, K. (2010). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(5), 893-901. doi: 10.1200/JCO.2009.27.0660.
93. Rubinstein, W. S.; O'Neill, S. M.; Peters, J. A.; Rittmeyer, L. J.; Stadler, M. P. (2002). Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. Oncology (Williston Park, N.Y.), 16(8), 1082-1094. discussion 1094, 1097-1099.
94. Rubinstein, W. S.; Jiang, H.; Dellefave, L.; Rademaker, A. W. (2009). Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 11(9), 629-639. doi: 10.1097/GIM.0b013e3181afd322.
95. Saadatmand, S.; Rutgers, E. J. T.; Tollenaar, R. A. E. M.; Zonderland, H. M.; Ausems, M. G. E. M.; Keymeulen, K. B. M. I.; et al. (2012). Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial. BMC Cancer, 12, 440. doi: 10.1186/1471-2407-12-440.
96. Schlich-Bakker, K. J.; ten Kroode, H. F. J.; Ausems, M. G. E. M. (2006). A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Education and Counseling, 62(1), 13-20. doi: 10.1016/j.pec.2005.08.012.
97. Schwartz, R. S.; D'Andrea, A. D. (2010). Susceptibility Pathways in Fanconi's Anemia and Breast Cancer. New England Journal of Medicine, 362(20), 1909-1919. doi: 10.1056/NEJMra0809889.
98. Seal, S.; Thompson, D.; Renwick, A.; Elliott, A.; Kelly, P.; Barfoot, R.; et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 38(11), 1239-1241. doi: 10.1038/ng1902.
99. Secretary's Advisory Committee on Genetics, Health, and Society. (2006, February). Coverage and Reimbursement of Genetic Tests and Services.
100. Senter, L.; Clendenning, M.; Sotamaa, K.; Hampel, H.; Green, J.; Potter, J. D.; et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419-428. doi: 10.1053/j.gastro.2008. 04.026.
101. Shanley, S.; Fung, C.; Milliken, J.; Leary, J.; Barnetson, R.; Schnitzler, M.; et al. (2009). Breast cancer immunohistochemistry can be useful in triage of some HNPCC families. Familial Cancer, 8(3), 251-255. doi: 10.1007/s10689-008-9226-4.
102. Sherman, K. A.; Miller, S. M.; Shaw, L.-K.; Cavanagh, K.; Sheinfeld Gorin, S. (2013). Psychosocial approaches to participation in BRCA1/2 genetic risk assessment among African American women: a systematic review. Journal of Community Genetics. doi: 10.1007/s12687-013-0164-y.
103. Sistemas Genómicos - Working areas - Biomedicine - Medical Genetics Unit - Oncology. (n.d.). Retrieved October 31, 2013, from https://www.sistemasgenomicos.com/web-sg/webing/areas-biomedicina-ugm3.php
104. Stacey, S. N.; Sulem, P.; Johannsson, O. T.; Helgason, A.; Gudmundsson, J.; Kostic, J. P.; et al. (2006). The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland. PLoS Medicine, 3(7), e217. doi: 10.1371/journal.pmed.0030217.
105. Starink, T. M.; van der Veen, J. P.; Arwert, F.; de Waal, L. P.; de Lange, G. G.; Gille, J. J.; et al. (1986). The Cowden syndrome: a clinical and genetic study in 21 patients. Clinical genetics, 29(3), 222-233.
106. Starita, L. M.; Parvin, J. D. (2006). Substrates of the BRCA1-dependent ubiquitin ligase. Cancer Biology & Therapy, 5(2), 137-141.
107. Supreme Court Invalidates Patents on Breast and Ovarian Cancer Genes | American Civil Liberties Union. (n.d.). Retrieved October 14, 2013, from https://www.aclu.org/womens-rights/supreme-court-invalidates-patents-breast-and- ovarian-cancer-genes
108. Swan, M. (2010). Multigenic condition risk assessment in direct-to-consumer genomic services. Genetics in Medicine, 12(5), 279-288. doi: 10.1097/GIM.0b013e3181d5f73b.
109. Swift, M.; Morrell, D.; Massey, R. B.; Chase, C. L. (1991). Incidence of cancer in 161 families affected by ataxia-telangiectasia. The New England Journal of Medicine, 325(26), 1831-1836. doi: 10.1056/NEJM199112263252602.
110. Tabor, H. K.; Stock, J.; Brazg, T.; McMillin, M. J.; Dent, K. M.; Yu, J.-. H.; et al. (2012). Informed consent for whole genome sequencing: A qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. American Journal of Medical Genetics Part A, 158A(6), 1310-1319. doi: 10.1002/ajmg.a.35328.
111. Tan, M.-. H.; Mester, J. L.; Ngeow, J.; Rybicki, L. A.; Orloff, M. S.; Eng, C. (2012). Lifetime cancer risks in individuals with germline PTEN mutations. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 18(2), 400-407. doi: 10.1158/1078-0432.CCR-11- 2283.
112. Tavtigian, S. V.; Greenblatt, M. S.; Goldgar, D. E.; Boffetta, P. (2008). Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Human Mutation, 29(11), 1261-1264. doi: 10.1002/humu.20903.
113. Thompson, D.; Duedal, S.; Kirner, J.; McGuffog, L.; Last, J.; Reiman, A.; et al. (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. Journal of the National Cancer Institute, 97(11), 813-822. doi: 10.1093/jnci/dji141.
114. Thorstenson, Y. R.; Roxas, A.; Kroiss, R.; Jenkins, M. A.; Yu, K. M.; Bachrich, T.; et al. (2003). Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Research, 63(12), 3325-3333.
115. Trill, M. D.; Holland, J. (1993). Cross-cultural differences in the care of patients with cancer. General Hospital Psychiatry, 15(1), 21-30. doi: 10.1016/0163-8343(93)90087-5.
116. Tumor Syndromes (n.d.). Retrieved February 25th, 2014, from http://www.cegat.de/Tumor-syndromes-l=1-171.html.
117. Tung, N.; Silver, D. P. (2011). Chek2 DNA damage response pathway and inherited breast cancer risk. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(28), 3813-3815. doi: 10.1200/JCO.2011.37.1476.
118. Vasen, H. F.; Stormorken, A.; Menko, F. H.; Nagengast, F. M.; Kleibeuker, J. H.; Griffioen, G.; et al. (2001). MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 19(20), 4074-4080.
119. Vernarelli, J. A.; Roberts, J. S.; Hiraki, S.; Chen, C. A.; Cupples, L. A.; Green, R. C. (2010). Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. The American Journal of Clinical Nutrition, 91(5), 1402-1407. doi: 10.3945/ajcn.2009.28981.
120. Walsh, T.; Lee, M. K.; Casadei, S.; Thornton, A. M.; Stray, S. M.; Pennil, C.; et al. (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 107(28), 12629-12633. doi: 10.1073/pnas.1007983107.
121. Wang, Y.; Cortez, D.; Yazdi, P.; Neff, N.; Elledge, S. J.; Qin, J. (2000). BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes & Development, 14(8), 927-939.
122. Weischer, M.; Bojesen, S. E.; Ellervik, C.; Tybjaerg-Hansen, A.; Nordestgaard, B. G. (2008). CHEK21100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(4), 542-548. doi: 10.1200/JCO.2007.12.5922.
123. White, M.; Dorman, S. (2000). Confronting Information Overload. Journal of School Health, 70(4), 160-161.
124. Williams, C.; Brunskill, S.; Altman, D.; Briggs, A.; Campbell, H.; Clarke, M.; et al. (2006). Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment (Winchester, England), 10(34), iii-iv. ix-xi, 1-204.
125. Wu, X.; Platt, J. L.; Cascalho, M. (2003). Dimerization of MLH1 and PMS2 Limits Nuclear Localization of MutL. Molecular and Cellular Biology, 23(9), 3320-3328. doi: 10.1128/MCB.23.9.3320-3328.2003.
126. Yasmeen, S.; Hubbard, R. A.; Romano, P. S.; Zhu, W.; Geller, B. M.; Onega, T.; et al. (2012). Risk of advanced-stage breast cancer among older women with comorbidities. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 21(9), 1510-1519. doi: 10.1158/1055-9965.EPI-12-0320.
127. Zick, C. D.; Mathews, C. J.; Roberts, J. S.; Cook-Deegan, R.; Pokorski, R. J.; Green, R. C. (2005). Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Affairs (Project Hope), 24(2), 483-490. doi: 10.1377/hlthaff.24.2.483.